Related Experiment Video
Updated: Sep 30, 2025
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Compressing the Timelines for Development and Delivery: Accelerating Access to Triple-Drug Therapy to Eliminate
Abstract:
The traditional timeline for a new innovation in public health to move from initial proof of concept to introduction into national programs is sequential and can take decades. Here, we discuss the development of a new drug therapy for lymphatic filariasis (LF) to help progress toward elimination as a public health problem and how this process was accelerated by a group of partners working together. This article documents the way that these partners worked together and made decisions that made it possible to accelerate the process of the development and introduction of the triple-drug therapy involving ivermectin, diethylcarbamazine, and albendazole (IDA). The partners were able to condense the development timeline from the first clinical efficacy data to delivery in a country program for the triple-drug therapy from a projected ∼28 years to less than 5 years while maintaining all of the safety standards. The approach required understanding stakeholders, their roles, need for data to inform decisions, and then looking at timelines focused on prioritizing activities that inform decision-making. This process relied on a close engagement of all stakeholders and good communication. Through this exercise, additional early data review points were added to study designs, studies were run in parallel not sequentially, and a plan put in place to engage all stakeholders necessary for adoption and uptake throughout the process, so they were prepared to make decisions as data became available. This process could provide some insights into how global health can work together in new ways to accelerate the availability of interventions and strategies to promote health and well-being.
Insights
Accelerating drug therapy for lymphatic filariasis (LF) involved a collaborative approach, condensing a 28-year timeline to under 5 years. This partnership ensured rapid delivery of the triple-drug therapy (IDA) while maintaining safety.
Area of Science:
- Global Health
- Drug Development
- Public Health Interventions
Background:
- Traditional public health innovations take decades to implement.
- Lymphatic filariasis (LF) elimination requires accelerated therapeutic strategies.
- A multi-partner collaboration was formed to expedite a new drug therapy.
Purpose of the Study:
- To document the accelerated development and introduction of a triple-drug therapy for LF.
- To analyze the collaborative decision-making process that shortened timelines.
- To demonstrate a model for accelerating global health interventions.
Main Methods:
- A collaborative framework involving diverse stakeholders was established.
- Decision-making was informed by continuous data review and stakeholder engagement.
- Study designs were modified for parallel execution and early data feedback loops.
Main Results:
- The development and introduction timeline for the triple-drug therapy (IDA) was reduced from an estimated 28 years to less than 5 years.
- Safety standards were maintained throughout the accelerated process.
- Effective stakeholder engagement and communication were crucial for success.
Conclusions:
- Collaborative approaches and adaptive study designs can significantly accelerate the delivery of public health interventions.
- This model offers insights for expediting the availability of new health strategies globally.
- Streamlined development and introduction processes are key to addressing public health challenges like LF.
